Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


User Fee Discussions Include Funding Parts Of FDA Regulatory Science Plan

Executive Summary

Commissioner Margaret Hamburg’s plans to improve regulatory science at FDA could benefit from application user fees, based on PDUFA negotiations.

You may also be interested in...

Orphan Designation Removals To Be Revealed By FDA

List will include whether a designation was lost, but not why, FDA says in final rule clarifying and updated 1992 orphan drug regulations.

Targeted Therapies On FDA’s Orphan Designation Radar

As personalized medicine continues to grow, FDA is watching to see if there is a rise in orphan designations for products targeting a “smaller slice” of a common disease.

PDUFA V: Sentinel, Regulatory Science Upgrades Could Gain User Fee Funding

FDA’s Sentinel Initiative appears to be gaining support through the Prescription Drug User Fee Act, although industry is not interested in blindly pumping user fee revenue into the project.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts